Qiagen NV (NASDAQ:QGEN) will issue its quarterly earnings data on Tuesday, February 2nd. Analysts expect the company to announce earnings of $0.32 per share for the quarter.

A hedge fund recently raised its stake in Qiagen NV stock. Russell Frank Co raised its stake in shares of Qiagen NV (NASDAQ:QGEN) by 71.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 984,835 shares of the company’s stock after buying an additional 408,983 shares during the period. Russell Frank Co owned 0.42% of Qiagen NV worth $27,160,000 at the end of the most recent reporting period.

QGEN has been the subject of several recent analyst reports. Goldman Sachs cut their price objective on shares of Qiagen NV from $22.00 to $21.00 in a research report on Friday, October 30th. Cowen and Company raised their price objective on shares of Qiagen NV to $24.00 in a research report on Thursday, January 7th. Zacks Investment Research upgraded shares of Qiagen NV from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research report on Friday, October 9th. DZ Bank AG restated a “buy” rating on shares of Qiagen NV in a research report on Thursday, October 29th. Finally, Morgan Stanley restated a “buy” rating on shares of Qiagen NV in a research report on Friday, November 6th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $26.08.

Qiagen NV (NASDAQ:QGEN) traded up 1.43% on Friday, hitting $22.71. 1,471,935 shares of the company traded hands. The firm has a market capitalization of $5.29 billion and a P/E ratio of 52.81. The stock’s 50-day moving average is $24.92 and its 200 day moving average is $26.06. Qiagen NV has a 12 month low of $21.37 and a 12 month high of $28.53.

QIAGEN N.V. (NASDAQ:QGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Company’s bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.

12 Month Chart for NASDAQ:QGEN

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.